IL6 and type 2 diabetes mellitus: Research has revealed that in individuals with IR (including those with obesity and T2D), the gene expression of interleukin-6 (IL-6) in skeletal muscle is enhanced, accompanied by an augmented activation of the NF-κB pathway [27,28].